ACU (Acme United Corporation) Stock Analysis - News
Acme United Corporation (ACU) is a publicly traded Consumer Defensive sector company. As of May 21, 2026, ACU trades at $42.39 with a market cap of $158.51M and a P/E ratio of 16.84. ACU moved +0.14% today. Year to date, ACU is +5.32%; over the trailing twelve months it is +7.81%. Its 52-week range spans $34.35 to $47.31. Rallies surfaces ACU's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in ACU news today?
Acme United Q1 Sales Up 14% to $52.3M, Earnings Down 40%: Net sales rose 14% to $52.3 million in Q1 on My Medic acquisition and 6% organic growth. Net income fell 40% to $1.0 million due to higher tariffs, quality assurance expenses and rising healthcare costs.
OLSCHAN BRIAN S sold 1.00K (~$40.05K) on Jun 3, 2025.
OLSCHAN BRIAN S sold 809 (~$32.32K) on Jun 2, 2025.
OLSCHAN BRIAN S sold 306 (~$12.21K) on May 20, 2025.
ACU Analyst Consensus
ACU analyst coverage data. Average price target: $0.00.
Common questions about ACU
What changed in ACU news today?
Acme United Q1 Sales Up 14% to $52.3M, Earnings Down 40%: Net sales rose 14% to $52.3 million in Q1 on My Medic acquisition and 6% organic growth. Net income fell 40% to $1.0 million due to higher tariffs, quality assurance expenses and rising healthcare costs.
Does Rallies summarize ACU news?
Yes. Rallies summarizes ACU news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is ACU research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ACU. It does not provide personalized investment advice.
